A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients
Status:
Completed
Trial end date:
2009-01-16
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to examine the effects of SB-480848 on plasma
lipoprotein associated phospholipase A2 (Lp-PLA2) activity in dyslipidemic patients during a
4-week treatment with SB-480848.